References
death, tumor necrosis
ADVERSE EVENTS, TUMOR NECROSIS
CONSORT 2010 flow diagram showing patient enrollment, randomization, and follow-up.Kaplan–Meier curve demonstrating survival according to treatment in the anakinra and placebo groups. Survival of all individuals exposed to anakinra is shown in blue, and survival of the placebo group is shown in red.Baseline demographic characteristics of the participants enrolled in the study and included in the intent-to-treat analysis.SD, standard deviation.Baseline clinical characteristics of the participants enrolled in the study and included in the intent-to-treat analysis.* Defined as patient requiring oxygen support >6 L per minute via nasal cannula. ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; INR, international normalized ratio; IU, international unit; LDH, lactate dehydrogenase; MICU, medical intensive care unit; N/A, not applicable; ULN, upper limit of normal; WBC, white blood cell count.Patient outcomes in the anakinra and placebo groups, intent-to-treat (ITT) analysis; N (%) represented unless otherwise stated.Categorical variables are reported as absolute number (percentage). Cytokine levels in the anakinra and placebo groups at Day 0 and Day 10. Mean with standard error of the mean reported, unless otherwise specified.TNF, tumor necrosis factor; ULN, upper limit of normal. * Data missing for 3 participants due to death prior to Day 10. Adverse and serious adverse events; N (%) represented unless otherwise stated.